Quick Answer
Bone Biologics Corp reported R&D Expense of $1.06 million for fiscal year 2025.
Bone Biologics Corp R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $1.06M | -50.2% |
| 2024 | $2.13M | -69.2% |
| 2023 | $6.91M | +337.4% |
| 2022 | $1.58M | +1824.9% |
| 2021 | $82.0K | -75.9% |
| 2020 | $340.7K | -68.9% |
| 2019 | $1.10M | +948.1% |
| 2018 | $104.5K | -92.6% |
| 2017 | $1.42M | -86.1% |
| 2016 | $10.17M | +177.3% |
| 2015 | $3.67M | +488.0% |
| 2014 | $623.5K | +231.2% |
| 2013 | $188.2K | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $187.8K | -56.3% | -2.0% |
| June 30, 2025 | $191.6K | -45.3% | -54.8% |
| March 31, 2025 | $423.6K | +72.4% | -1.4% |
| September 30, 2024 | $429.7K | -72.7% | +22.6% |
| June 30, 2024 | $350.4K | -84.7% | +42.7% |
| March 31, 2024 | $245.6K | -90.5% | -84.4% |
| September 30, 2023 | $1.57M | +104.7% | -31.4% |
| June 30, 2023 | $2.30M | +12941.2% | -11.4% |
- Bone Biologics Corp showed a decrease of -50.2% in R&D Expense compared to the prior fiscal year.
- Over the 2013–2025 period, Bone Biologics Corp’s r&d expense has grown by 463.2% (from $188.2 thousand to $1.06 million).
- The most recent figure is from Bone Biologics Corp’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 2, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: